



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

8 February 2023

Investor Webinar Recording

MELBOURNE — **Imagion Biosystems Limited (ASX: IBX)**, a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce that a recording of yesterday's investor webinar can be found on our website at:

<https://imagionbiosystems.com/webinar-070223/>

Bob Proulx, our CEO and Dr. Yalia Jayalakshmi, our Chief Development Officer discussed our latest positive independent review including: a discussion on what this means for Imagion Biosystems; how this accelerates our path to market; an update on the future of our technology; and a Q&A session fielded questions from attendees.

Thanks again to those that were able to attend. Please send any further questions (or those we didn't have time to answer) or feedback to investor@imagionbio.com.

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit www.imagionbiosystems.com

Authorisation & Additional information

This announcement was authorised by the Company Secretary of Imagion Biosystems Limited.

U.S. Media Contact:

Casie Ost

Casie.ost@imagionbio.com

+1-619-693-4428

Australian Media & Investor Relations:

Hannah Howlett, WE Communications

We-AUImagionBiosystems@we-worldwide.com

+61 (0) 450648064

Imagion Biosystems Limited

ACN 616 305 027

Level 25, 525 Collins Street, Melbourne VIC 3000

www.imagionbiosystems.com